Takeda and Cognition Kit partner to pilot wearables in patients with Major Depressive Disorder (MDD)
Posted on 24 February 2017
Takeda Pharmaceuticals U.S.A. and Cognition Kit Limited announce a collaboration to pilot the use of a specially designed app on an Apple Watch wearable to monitor and assess cognitive function in patients with Major Depressive Disorder (MDD).
Posted on 25 January 2017
Cambridge Cognition today announces it has received 510(k) clearance from the U.S. Food and Drug Administration ('FDA') to market its CANTAB Mobile product as a medical device in the U.S.
Posted on 12 January 2017
Autifony Therapeutics recently presented a poster at the American College of Neuropsychopharmacology following their first human Phase I study in healthy male volunteers to investigate a novel treatment for the positive, negative and cognitive symptoms of schizophrenia.
Posted on 11 January 2017
Cambridge Cognition has chosen The Cure Parkinson’s Trust (CPT) as beneficiary Charity of the Year for 2017.